荣昌生物(09995.HK)：泰它西普(商品名：泰爱)获得国家药监局完全批准用于治疗类风湿关节炎患者

格隆汇资讯07-22

格隆汇7月22日丨荣昌生物(09995.HK)公告，泰它西普(商品名：泰爱)正式获得中国国家药品监督管理局(NMPA)在中国上市的完全批准，用于与甲氨蝶呤联合治疗针对甲氨蝶呤疗效不佳的中、重度活动性类风湿关节炎(RA)成人患者。泰它西普在本适应症获得批准，是基于一项在RA患者中开展的以甲氨蝶呤为基础治疗的随机、双盲、安慰剂对照、多中心的III期临床研究，共入组479例患者。该研究旨在评估泰它西普...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2453214765?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-22 19:22","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2453214765","market":"hk","top_or_hot":-1,"title":"荣昌生物(09995.HK)：泰它西普(商品名：泰爱)获得国家药监局完全批准用于治疗类风湿关节炎患者","media":"格隆汇资讯","content":"<div>\n<p>格隆汇7月22日丨荣昌生物(09995.HK)公告，泰它西普(商品名：泰爱)正式获得中国国家药品监督管理局(NMPA)在中国上市的完全批准，用于与甲氨蝶呤联合治疗针对甲氨蝶呤疗效不佳的中、重度活动性类风湿关节炎(RA)成人患者。泰它西普在本适应症获得批准，是基于一项在RA患者中开展的以甲氨蝶呤为基础治疗的随机、双盲、安慰剂对照、多中心的III期临床研究，共入组479例患者。该研究旨在评估泰它西普...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072219230695e81c87&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>荣昌生物(09995.HK)：泰它西普(商品名：泰爱)获得国家药监局完全批准用于治疗类风湿关节炎患者</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n荣昌生物(09995.HK)：泰它西普(商品名：泰爱)获得国家药监局完全批准用于治疗类风湿关节炎患者\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-22 19:22 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072219230695e81c87&s=b><strong>格隆汇资讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>格隆汇7月22日丨荣昌生物(09995.HK)公告，泰它西普(商品名：泰爱)正式获得中国国家药品监督管理局(NMPA)在中国上市的完全批准，用于与甲氨蝶呤联合治疗针对甲氨蝶呤疗效不佳的中、重度活动性类风湿关节炎(RA)成人患者。泰它西普在本适应症获得批准，是基于一项在RA患者中开展的以甲氨蝶呤为基础治疗的随机、双盲、安慰剂对照、多中心的III期临床研究，共入组479例患者。该研究旨在评估泰它西普...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072219230695e81c87&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072219230695e81c87&s=b","article_id":"2453214765","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072219230695e81c87&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2453214765","pubTimestamp":1721647376,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"格隆汇7月22日丨荣昌生物公告，泰它西普正式获得中国国家药品监督管理局在中国上市的完全批准，用于与甲氨蝶呤联合治疗针对甲氨蝶呤疗效不佳的中、重度活动性类风湿关节炎成人患者。泰它西普在本适应症获得批准，是基于一项在RA患者中开展的以甲氨蝶呤为基础治疗的随机、双盲、安慰剂对照、多中心的III期临床研究，共入组479例患者。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","09995":"荣昌生物","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1574":"生物医药B类股","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1583":"高瓴概念"},"translate_title":"Rongchang Biotech (09995. HK): Tatacept (trade name: Taiai) was fully approved by the State Food and Drug Administration for the treatment of patients with rheumatoid arthritis","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"格隆汇7月22日丨荣昌生物(09995.HK)公告，泰它西普(商品名：泰爱)正式获得中国国家药品监督管理局(NMPA)在中国上市的完全批准，用于与甲氨蝶呤联合治疗针对甲氨蝶呤疗效不佳的中、重度活动性类风湿关节炎(RA)成人患者。泰它西普在本适应症获得批准，是基于一项在RA患者中开展的以甲氨蝶呤为基础治疗的随机、双盲、安慰剂对照、多中心的III期临床研究，共入组479例患者。该研究旨在评估泰它西普联合甲氨喋呤治疗对甲氨喋呤疗效不佳的中重度类风湿关节炎患者的有效性和安全性。最新研究数据显示，泰它西普显著提升RA患者ACR20应答率，24周ACR20应答率67.4%，48周ACR20应答率持续提高，达72.2%；显著延缓RA患者的关节结构损害，92.8%患者24周无影像学进展，89.9%患者48周无影像学进展；显著改善RA患者的炎症水平和患者身体机能，缓解疼痛；达标(DAS28-ESR≤3.2)患者比例持续增加至48周，且安全可耐受。泰它西普(RC18，商品名：泰爱)是公司专有用于治疗自身免疫性疾病的新型融合蛋白，由人跨膜激活剂及钙调节剂和亲环素配体相互作用因子(TACI)受体的胞外域以及人免疫球蛋白G(IgG)的可结芯片段(Fc)域构成。泰它西普靶向两类对B淋巴细胞发育至关重要的细胞信号分子：B淋巴细胞刺激因子(BLyS)和增殖诱导配体(APRIL)，得以有效降低B细胞介导的自身免疫应答，自身免疫应答与多种自身免疫性疾病有关。该产品已于2023年11月正式获得中国国家药品监督管理局(NMPA)在中国的完全上市批准，用于治疗系统性红斑狼疮(SLE)。公司现正就泰它西普用于治疗自身免疫性疾病领域的其他多种适应症开展II期或III期临床试验，试图解决该治疗领域大量未满足或未充分满足的医疗需求。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2453214765"}